Acute inflammatory biomarker profiles predict depression risk following moderate to severe traumatic brain injury

Journal of Head Trauma Rehabilitation

Volumn 30, Issue 3, 2015, Pages 207-218

  Juengst, Shannon B ^a   Kumar, Raj G ^a   Failla, Michelle D ^a,b   Goyal, Akash ^a   Wagner, Amy Kathleen ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Brain injury; Cytokines; Depression; Inflammation; Interleukins; Intracellular adhesion molecule 1; Vascular cell adhesion molecule 1

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; SOLUBLE VASCULAR ADHESION MOLECULE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANOSOGNOSIA; ARTICLE; CHRONIC INFLAMMATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE SEVERITY; DSM-IV; FEMALE; GLASGOW COMA SCALE; HUMAN; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; PATIENT HEALTH QUESTIONNAIRE; PATIENT HEALTH QUESTIONNAIRE 9; POSTTRAUMATIC DEPRESSION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TRAUMATIC BRAIN INJURY; BRAIN INJURY; DEPRESSIVE DISORDER; METABOLISM; PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; TIME; YOUNG ADULT;

ADULT; ANTIGENS, CD95; BIOMARKERS; BRAIN INJURIES; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKINS; MALE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84936755637     PISSN: 08859701     EISSN: 1550509X     Source Type: Journal    
DOI: 10.1097/HTR.0000000000000031     Document Type: Article

References (78)

1. Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, McIntosh TK. The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol. 2001;24(1-3):169-181. doi:10.1385/MN:24:1-3:169.
2. Centers for Disease Control and Prevention. CDC grand rounds: reducing severe traumatic brain injury in the United States. MMWR Morb Mortal Wkly Rep. 2013;62(27):549-552.
3. Gilliam F, Kanner AM, Sheline Y. Depression andBrain Dysfunction. Oxford, UK: Taylor & Francis; 2005.
4. Hibbard MR, Uysal S, Kepler K, Bogdany J, Silver J. Axis I psychopathology in individuals with traumatic brain injury. J Head Trauma Rehabil. 1998;13(4):24-39.
5. Ownsworth T, Fleming J, Haines T, et al. Development of depressive symptoms during early community reintegration after traumatic brain injury. J Int Neuropsychol Soc JINS. 2011;17(1):112-119. doi:10.1017/S1355617710001311.
6. Pagulayan KF, Hoffman JM, Temkin NR, Machamer JE, Dikmen SS. Functional limitations and depression after traumatic brain injury: examination of the temporal relationship. Arch Phys Med Rehabil. 2008;89(10):1887-1892. doi:10.1016/j.apmr.2008.03.019.
7. Lettieri JR, Failla MD, Brett CA, et al. Depression, seizures, and reduced cognitive performance modulate quality of life through functional outcome after traumatic brain injury. J Neurotrauma. 2013;30(8):B129. doi:10.1089/neu.2013.9938.
8. Hibbard MR, Ashman TA, Spielman LA, Chun D, Charatz HJ, Melvin S. Relationship between depression and psychosocial functioning after traumatic brain injury. Arch Phys Med Rehabil. 2004;85(4) (suppl 2):S43-S53.
9. Lin M-R, Chiu W-T, Chen Y-J, Yu W-Y, Huang S-J, Tsai MD. Longitudinal changes in the health-related quality of life during the first year after traumatic brain injury. Arch Phys Med Rehabil. 2010;91(3):474-480. doi:10.1016/j.apmr.2009.10 .031.
10. Failla MD, Burkhardt JN,Miller MA, et al. Variants of SLC6A4 in depression risk following severe TBI. Brain Inj BI. 2013;27(6):696-706. doi:10.3109/02699052.2013.775481.
11. Fann J, Hart T, University of Washington Model Systems Knowledge Translation Center. Depression after traumatic brain injury. Arch Phys Med Rehabil. 2013;94(4):801-802. doi:10.1016/j.apmr.2012.04.001.
12. Lanctôt KL, Rapoport MJ, Chan F, et al. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj BI. 2010;24(7/8):959-969. doi:10.3109/02699051003789229.
13. Hart T, Hoffman JM, Pretz C, Kennedy R, Clark AN, Brenner LA. A longitudinal study of major and minor depression following traumatic brain injury. Arch Phys Med Rehabil. 2012;93(8):1343-1349. doi:10.1016/j.apmr.2012.03.036.
14. Ownsworth TL, Oei TP. Depression after traumatic brain injury: conceptualization and treatment considerations. Brain Inj BI. 1998;12(9):735-751.
15. Fann JR, Hart T, Schomer KG. Treatment for depression after traumatic brain injury: a systematic review. J Neurotrauma. 2009;26(12):2383-2402. doi:10.1089/neu.2009.1091.
16. Bombardier CH, Fann JR, Temkin NR, Esselman PC, Barber J, Dikmen SS. Rates of major depressive disorder and clinical outcomes following traumatic brain injury. JAMA. 2010;303(19):1938-1945. doi:10.1001/jama.2010.599.
17. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9(11):853-858. doi:10.1006/cyto.1997. 0238.
18. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acutephase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology. 1997;35(3):123-127. doi:10.1159/000119332.
19. Namas R, Ghuma A, Hermus L, et al. The acute inflammatory response in trauma/hemorrhage and traumatic brain injury: current state and emerging prospects. Libyan JMed. 2009;4(3):97-103. doi:10.4176/090325.
20. Cone JB. Inflammation. Am J Surg. 2001;182(6):558-562.
21. Savage CD, Lopez-Castejon G, Denes A, Brough D. NLRP3- Inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol. 2012;3:288. doi:10.3389/fimmu.2012.00288.
22. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol. 2013;4:18. doi:10.3389/fneur.2013.00018.
23. Kushner I. Semantics, inflammation, cytokines and common sense. Cytokine Growth Factor Rev. 1998;9(3/4):191-196.
24. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31. doi:10.1016/j.it.2005.11.006.
25. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201-217. doi:10.1016/j.pnpbp.2004.11.003.
26. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246:199-229. doi:10.1016/j.neuroscience .2013.04.060.
27. Fischer A, Otte C, Krieger T, et al. Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression. Psychoneuroendocrinology. 2012;37(10):1712-1718. doi:10.1016/j.psyneuen.2012.03.001.
28. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011;32(1):7-24.
29. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009;29(2):309-320. doi:10.1016/j.iac.2009.02. 008.
30. Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin. 2006;24(3):441-460. doi:10.1016/j.ncl.2006.03.003.
31. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha- induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54(9):906-914.
32. Jones I, Craddock N. Candidate gene studies of bipolar disorder. Ann Med. 2001;33(4):248-256.
33. Wagner AK, McCullough EH, Niyonkuru C, et al. Acute serum hormone levels: characterization and prognosis after severe traumatic brain injury. J Neurotrauma. 2011;28(6):871-888. doi:10.1089/neu.2010.1586.
34. Easton AS. Neutrophils and stroke-Can neutrophils mitigate disease in the central nervous system? Int Immunopharmacol. 2013;17(4):1218-1225. doi:10.1016/j.intimp.2013.06.015.
35. Futosi K, Fodor S,Mócsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int Immunopharmacol. 2013;17(3):638-650. doi:10.1016/j.intimp.2013.06.034.
36. Jovanova-Nesic K, Shoenfeld Y, Spector NH. Aluminum excytotoxicity and neuroautotoimmunity: the role of the brain expression of CD32+ (Fcγ RIIa), ICAM-1+ and CD3+ in aging. Curr Aging Sci. 2012;5(3):209-217.
37. Loane DJ, Byrnes KR. Role of microglia in neurotrauma. Neurother J Am Soc Exp Neurother. 2010;7(4):366-377. doi:10.1016/j.nurt.2010.07.002.
38. Pleines UE, Stover JF, Kossmann T, Trentz O, Morganti- KossmannMC. Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury. J Neurotrauma. 1998;15(6):399-409.
39. Uzan M, Erman H, Tanriverdi T, Sanus GZ, Kafadar A, Uzun H. Evaluation of apoptosis in cerebrospinal fluid of patients with severe head injury. Acta Neurochir (Wien). 2006;148(11):1157-1164; discussion. doi:10.1007/s00701-006-0887-1.
40. Dimopoulos N, Piperi C, Salonicioti A, et al. Elevation of plasma concentration of adhesion molecules in late-life depression. Int J Geriatr Psychiatry. 2006;21(10):965-971. doi:10.1002/gps.1592.
41. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24(suppl 1):S1-106. doi:10.1089/neu.2007.9999.
42. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872):81-84.
43. Fann JR, Bombardier CH, Dikmen S, et al. Validity of the Patient Health Questionnaire-9 in assessing depression following traumatic brain injury. J Head Trauma Rehabil. 2005;20(6):501-511.
44. Kroenke K, Spitzer RL,Williams JB. The PHQ-9: validity of a brief depression severity measure. JGen Intern Med. 2001;16(9):606-613.
45. Seel RT, Macciocchi S, Kreutzer JS. Clinical considerations for the diagnosis of major depression after moderate to severe TBI. J Head Trauma Rehabil. 2010;25(2):99-112. doi:10.1097/HTR.0b013e3181ce3966.
46. Depino A, Ferrari C, Pott Godoy MC, Tarelli R, Pitossi FJ. Differential effects of interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in specific brain regions. JNeuroimmunol. 2005;168(1/2):96-110. doi:10.1016/j.jneuroim.2005.07.009.
47. Leal MC, Casabona JC, Puntel M, Pitossi FJ. Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci. 2013;7:53. doi:10.3389/fncel.2013.00053.
48. Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline "predictors" and longitudinal "targets." Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2013;38(3):377-385. doi:10.1038/npp.2012.191.
49. Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70(3):374-383. doi:10.1002/ana.22455.
50. Maller JJ, Thomson RHS, Lewis PM, Rose SE, Pannek K, Fitzgerald PB. Traumatic brain injury, major depression, and diffusion tensor imaging: making connections. Brain Res Rev. 2010;64(1):213-240. doi:10.1016/j.brainresrev.2010.04.003.
51. Tsitsopoulos PP, Marklund N. Amyloid-β peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front Neurol. 2013;4:79. doi:10.3389/fneur.2013.00079.
52. Firbank MJ, Teodorczuk A, van der Flier WM, et al. Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. Br J Psychiatry J Ment Sci. 2012;201(1):40-45. doi:10.1192/bjp.bp.111.098897.
53. Jorm AF, Anstey KJ, Christensen H, et al. MRI hyperintensities and depressive symptoms in a community sample of individuals 60-64 years old. Am J Psychiatry. 2005;162(4):699-705. doi:10.1176/appi.ajp.162.4.699.
54. Köhler S, Thomas AJ, Lloyd A, Barber R, AlmeidaOP, O'Brien JT. White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression. Br J Psychiatry JMent Sci. 2010;196(2):143-149. doi:10.1192/bjp.bp.109.071399.
55. Sheline YI, Price JL, Vaishnavi SN, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry. 2008;165(4):524-532. doi:10.1176/appi.ajp.2007.07010175.
56. Thomas AJ, Perry R, Kalaria RN,Oakley A, McMeekin W, O'Brien JT. Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. Int J Geriatr Psychiatry. 2003;18(1):7-13. doi:10.1002/gps.720.
57. Kämppä N, Mäkelä K-M, Lyytikäinen L-P, et al. Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: the vitality 90+ study. Exp Gerontol. 2013;48(11):1167-1172. doi:10.1016/j.exger.2013.07.009.
58. Isingrini E, Belzung C, d' Audiffret A, Camus V. Early and lateonset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2011;19(4):335-346. doi:10.1097/JGP.0b013e318202bc42.
59. Bao F, Shultz SR, Hepburn JD, et al. A CD11d monoclonal antibody treatment reduces tissue injury and improves neurological outcome after fluid percussion brain injury in rats. J Neurotrauma. 2012;29(14):2375-2392. doi:10.1089/neu.2012.2408.
60. Lehto SM, Huotari A, Niskanen L, et al. Serum IL-7 and G-CSF in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):846-851. doi:10.1016/j.pnpbp.2010.03.033.
61. Kim Y-K, Na K-S, Shin K-H, Jung H-Y, Choi S-H, Kim J-B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1044-1053. doi:10.1016/j.pnpbp.2007.03.004.
62. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99(11):3892-3904.
63. Kraus MR, Al-Taie O, Schäfer A, Pfersdorff M, Lesch K-P, Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007;132(4):1279-1286. doi:10.1053/j.gastro.2007.02.053.
64. Smith AK, Simon JS, Gustafson EL, et al. Association of a polymorphism in the indoleamine-2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C. Mol Psychiatry. 2012;17(8):781-789. doi:10.1038/mp.2011.67.
65. Draper K, Ponsford J. Long-term outcome following traumatic brain injury: a comparison of subjective reports by those injured and their relatives. Neuropsychol Rehabil. 2009;19(5):645-661. doi:10.1080/17405620802613935.
66. Soo C, Tate RL. Psychological treatment for anxiety in people with traumatic brain injury. In: Cochrane Database of Systematic Reviews. Hoboken, NJ: John Wiley & Sons Ltd; 1996. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005239.pub2/abstract. Accessed June 25, 2013.
67. Neurobehavioral Guidelines Working Group Warden DL, Gordon B, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. JNeurotrauma. 2006;23(10):1468-1501. doi:10.1089/neu.2006.23.1468.
68. Littrell JL. Taking the perspective that a depressive state reflects inflammation: implications for the use of antidepressants. Front Psychol. 2012;3:297. doi:10.3389/fpsyg.2012.00297.
69. Pineda EA, Hensler JG, Sankar R, Shin D, Burke TF, Mazarati AM. Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression. Neurother J Am Soc Exp Neurother. 2012;9(2):477-485. doi:10.1007/s13311-012-0110-4.
70. Karson A, Demirtaş T, Bayramgürler D, Balci F, Utkan T. Chronic administration of infliximab (TNF-α inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress. Basic Clin Pharmacol Toxicol. 2013;112(5):335-340. doi:10.1111/bcpt.12037.
71. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry Chic Ill. 2013;70(1):31-41. doi:10.1001/2013.jamapsychiatry.4.
72. Hallberg L, Janelidze S, Engstrom G, Wisén AGM, Westrin A, Brundin L. Exercise-induced release of cytokines in patients with major depressive disorder. J Affect Disord. 2010;126(1/2):262-267. doi:10.1016/j.jad.2010.02.133.
73. Hoffman JM, Bell KR, Powell JM, et al. A randomized controlled trial of exercise to improve mood after traumatic brain injury. PM R. 2010;2(10):911-919. doi:10.1016/j.pmrj.2010.06. 008.
74. Wise EK, Hoffman JM, Powell JM, Bombardier CH, Bell KR. Benefits of exercise maintenance after traumatic brain injury. Arch Phys Med Rehabil. 2012;93(8):1319-1323. doi:10.1016/j.apmr.2012.05.009.
75. Khajehnasiri F, Mortazavi SB, Allameh A, Akhondzadeh S. Effect of omega-3 and ascorbic acid on inflammation markers in depressed shift workers in Shahid Tondgoyan Oil Refinery, Iran: a randomized double-blind placebo-controlled study. J Clin Biochem Nutr. 2013;53(1):36-40. doi:10.3164/jcbn.12-98.
76. Orr SK, Trépanier M-O, Bazinet RP. n-3 Polyunsaturated fatty acids in animal models with neuroinflammation. Prostaglandins Leukot Essent Fatty Acids. 2013;88(1):97-103. doi:10.1016/j.plefa.2012.05.008.
77. Luberto CM, White C, Sears RW, Cotton S. Integrative medicine for treating depression: an update on the latest evidence. Curr Psychiatry Rep. 2013;15(9):391. doi:10.1007/s11920-013-0391-2.
78. Qureshi NA, Al-Bedah AM. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat. 2013;9:639-658. doi:10.2147/NDT.S43419.